Amneal Pharmaceuticals Inc [AMRX] stock prices are up 1.99% to $8.21 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AMRX shares have gain 4.99% over the last week, with a monthly amount drifted -1.44%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on June 06, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $12. Previously, JP Morgan upgraded its rating to Overweight on February 24, 2025, and elevated its price target to $12. On September 06, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $9 on the stock. Goldman upgraded its rating to a Buy and raised its price target to $6.50 on March 08, 2021. Guggenheim upgraded its rating to Buy for this stock on December 14, 2020, but kept the price target unchanged to $5.50. In a note dated December 14, 2020, Barclays upgraded an Overweight rating on this stock and boosted its target price from $4.50 to $6.
The stock price of Amneal Pharmaceuticals Inc [AMRX] has been fluctuating between $6.68 and $9.48 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $8.21 at the most recent close of the market. An investor can expect a potential return of 33.98% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
The Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.85B for trailing twelve months, representing a surge of 3.24%. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.02 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Amneal Pharmaceuticals Inc [NASDAQ:AMRX]’s Current Ratio is 1.43. Further, the Quick Ratio stands at 0.88, while the Cash Ratio is 0.06. Considering the valuation of this stock, the price to sales ratio is 0.90 and price to earnings (TTM) ratio is 1207.35.
Transactions by insiders
Recent insider trading involved Patel Gautam, Director, that happened on Jun 16 ’25 when 94906.0 shares were sold. Director, Patel Gautam completed a deal on Jun 10 ’25 to sell 56426.0 shares. Meanwhile, Executive Vice President Shah Nikita sold 49140.0 shares on May 16 ’25.
